DRMA Stock Earnings Dermata Therapeutics Misses EPS for Q2 2024

DRMA Stock  USD 1.08  0.03  2.86%   
About 54% of Dermata Therapeutics' investors are presently thinking to get in. The analysis of the overall investor sentiment regarding Dermata Therapeutics suggests that some traders are interested. The current market sentiment, together with Dermata Therapeutics' historical and current headlines, can help investors time the market. In addition, many technical investors use Dermata Therapeutics stock news signals to limit their universe of possible portfolio assets.
  
DRMA stock results show that Dermata Therapeutics missed analyst estimates for earnings per share the second quarter of 2024.

Read at investorplace.com
sbwire news
  

Dermata Therapeutics Investor Sentiment by Other News Outlets

Investor sentiment, mood or attitude towards Dermata Therapeutics can have a significant impact on its stock price or the market as a whole. This sentiment can be positive or negative, and various factors, such as economic indicators, news events, or market trends, can influence it. When investor sentiment is positive, investors are more likely to buy stocks, increasing demand and increasing the stock price. Positive investor sentiment can be driven by good news about the company or the broader market, such as solid earnings reports or positive economic data.
Note that negative investor sentiment can cause investors to sell stocks, leading to a decrease in demand and a drop in the stock price. Negative sentiment can be driven by factors such as poor earnings reports, negative news about the company or industry, or broader economic concerns. It's important to note that investor sentiment is just one of many factors that can affect stock prices. Other factors, such as company performance, industry trends, and global economic conditions, can also play a significant role in determining the value of a stock.

Dermata Therapeutics Fundamental Analysis

We analyze Dermata Therapeutics' financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Dermata Therapeutics using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of Dermata Therapeutics based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.

Book Value Per Share

Book Value Per Share Comparative Analysis

Dermata Therapeutics is currently under evaluation in book value per share category among its peers. Book Value per Share (B/S) can be calculated by subtracting liabilities from assets, and then dividing it by the total number of currently outstanding shares. It indicates the level of safety associated with each common share after removing the effects of liabilities. In other words, a shareholder can use this ratio to see how much he or she can sell the stake in the company in the event of a liquidation.

Dermata Therapeutics Potential Pair-trading

One of the popular trading techniques among algorithmic traders is to use market-neutral strategies where every trade hedges away some risk. Because there are two separate transactions required, even if one position performs unexpectedly, the other equity can make up some of the losses. Below are some of the equities that can be combined with Dermata Therapeutics stock to make a market-neutral strategy. Peer analysis of Dermata Therapeutics could also be used in its relative valuation, which is a method of valuing Dermata Therapeutics by comparing valuation metrics with similar companies.

Peers

Dermata Therapeutics Related Equities

ZURAZura Bio   5.41   
0%
20.0%
ENSCEnsysce Biosciences   1.89   
0%
7.0%
PHIOPhio Pharmaceuticals   1.15   
0%
4.0%
SONNSonnet Biotherapeutics   1.89   
7.0%
0%
IMMXImmix Biopharma   2.25   
8.0%
0%
WINTWindtree Therapeutics   3.03   
11.0%
0%
REVBRevelation Biosciences   3.23   
12.0%
0%
ATNF180 Life   4.12   
15.0%
0%
CDIOCardio Diagnostics   4.90   
18.0%
0%
HEPAHepion Pharmaceuticals   7.55   
28.0%
0%
ZVSAZyVersa Therapeutics   8.06   
30.0%
0%
CYTOAltamira Therapeutics   26.83   
100.0%
0%

Complementary Tools for Dermata Stock analysis

When running Dermata Therapeutics' price analysis, check to measure Dermata Therapeutics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Dermata Therapeutics is operating at the current time. Most of Dermata Therapeutics' value examination focuses on studying past and present price action to predict the probability of Dermata Therapeutics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Dermata Therapeutics' price. Additionally, you may evaluate how the addition of Dermata Therapeutics to your portfolios can decrease your overall portfolio volatility.
Portfolio Dashboard
Portfolio dashboard that provides centralized access to all your investments
Bonds Directory
Find actively traded corporate debentures issued by US companies
Idea Analyzer
Analyze all characteristics, volatility and risk-adjusted return of Macroaxis ideas
Piotroski F Score
Get Piotroski F Score based on the binary analysis strategy of nine different fundamentals